Cargando…

Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents

Primary signet ring cell/histiocytoid carcinoma of the eyelid is a rare ocular malignancy and its diagnosis is often delayed. This neoplasm presents as an insidious, diffusely infiltrative mass in the periocular area that later infiltrates the orbit. An exenteration is usually indicated; however, ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei-Chi, Lin, Tai-Chi, Yeh, Yi-Chen, Ho, Hsiang-Ling, Tsai, Chieh-Chih, Chou, Teh-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985776/
https://www.ncbi.nlm.nih.gov/pubmed/33617508
http://dx.doi.org/10.3390/curroncol28010090
_version_ 1783668320020463616
author Wang, Lei-Chi
Lin, Tai-Chi
Yeh, Yi-Chen
Ho, Hsiang-Ling
Tsai, Chieh-Chih
Chou, Teh-Ying
author_facet Wang, Lei-Chi
Lin, Tai-Chi
Yeh, Yi-Chen
Ho, Hsiang-Ling
Tsai, Chieh-Chih
Chou, Teh-Ying
author_sort Wang, Lei-Chi
collection PubMed
description Primary signet ring cell/histiocytoid carcinoma of the eyelid is a rare ocular malignancy and its diagnosis is often delayed. This neoplasm presents as an insidious, diffusely infiltrative mass in the periocular area that later infiltrates the orbit. An exenteration is usually indicated; however, nearly one-third of patients develop local recurrence or metastasis. Morphologically, it resembles signet ring cell carcinoma of the stomach and breast, raising the possibility of mutations in CDH1, the gene encoding E-cadherin. To determine whether primary signet ring cell/histiocytoid carcinoma harbors the CDH1 mutation or other actionable mutations, we analyzed the tumor tissue via next-generation sequencing. We identified only one case of primary signet ring cell carcinoma of the eyelid with adequate DNA quality for sequencing from the pathological archive during the period 2000 to 2020. A comprehensive evaluation including histopathology, immunohistochemistry, and next-generation sequencing assay was performed on tumor tissue. Immunohistochemically, the tumor exhibited E-cadherin membranous staining with the aberrant cytoplasmic staining of β-catenin. Using next-generation sequencing, we demonstrated the mutation in the CDH1 gene. In addition, other clinically actionable mutations including ERBB2 and PIK3CA were also detected. The alterations in other actionable genes indicate a need for larger studies to evaluate the pathogenesis and potential therapies for primary signet ring cell/histiocytoid carcinoma of the eyelid.
format Online
Article
Text
id pubmed-7985776
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79857762021-03-24 Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents Wang, Lei-Chi Lin, Tai-Chi Yeh, Yi-Chen Ho, Hsiang-Ling Tsai, Chieh-Chih Chou, Teh-Ying Curr Oncol Case Report Primary signet ring cell/histiocytoid carcinoma of the eyelid is a rare ocular malignancy and its diagnosis is often delayed. This neoplasm presents as an insidious, diffusely infiltrative mass in the periocular area that later infiltrates the orbit. An exenteration is usually indicated; however, nearly one-third of patients develop local recurrence or metastasis. Morphologically, it resembles signet ring cell carcinoma of the stomach and breast, raising the possibility of mutations in CDH1, the gene encoding E-cadherin. To determine whether primary signet ring cell/histiocytoid carcinoma harbors the CDH1 mutation or other actionable mutations, we analyzed the tumor tissue via next-generation sequencing. We identified only one case of primary signet ring cell carcinoma of the eyelid with adequate DNA quality for sequencing from the pathological archive during the period 2000 to 2020. A comprehensive evaluation including histopathology, immunohistochemistry, and next-generation sequencing assay was performed on tumor tissue. Immunohistochemically, the tumor exhibited E-cadherin membranous staining with the aberrant cytoplasmic staining of β-catenin. Using next-generation sequencing, we demonstrated the mutation in the CDH1 gene. In addition, other clinically actionable mutations including ERBB2 and PIK3CA were also detected. The alterations in other actionable genes indicate a need for larger studies to evaluate the pathogenesis and potential therapies for primary signet ring cell/histiocytoid carcinoma of the eyelid. MDPI 2021-02-16 /pmc/articles/PMC7985776/ /pubmed/33617508 http://dx.doi.org/10.3390/curroncol28010090 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Wang, Lei-Chi
Lin, Tai-Chi
Yeh, Yi-Chen
Ho, Hsiang-Ling
Tsai, Chieh-Chih
Chou, Teh-Ying
Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title_full Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title_fullStr Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title_full_unstemmed Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title_short Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents
title_sort primary signet ring cell/histiocytoid carcinoma of the eyelid: somatic mutations in cdh1 and other clinically actionable mutations imply early use of targeted agents
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985776/
https://www.ncbi.nlm.nih.gov/pubmed/33617508
http://dx.doi.org/10.3390/curroncol28010090
work_keys_str_mv AT wangleichi primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents
AT lintaichi primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents
AT yehyichen primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents
AT hohsiangling primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents
AT tsaichiehchih primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents
AT choutehying primarysignetringcellhistiocytoidcarcinomaoftheeyelidsomaticmutationsincdh1andotherclinicallyactionablemutationsimplyearlyuseoftargetedagents